Precision therapeutics

Learn more about how Precision Epilepsy testing at Mayo Clinic Laboratories enables a holistic diagnostic care experience that supports better outcomes for patients with epilepsy.

Viral and pharmacogenomic testing help clinicians detect infection early, tailor immunosuppression, and improve long-term outcomes for organ transplant recipients.

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

Recognizing the powerful role genes can play in diagnosing illness and guiding treatment, the Division of Laboratory Genetics and Genomics at Mayo Clinic spearheaded a testing expansion, implementing and upgrading more than 60 advanced sequencing and biochemical assays in 2023 and planning for even more this year.

Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D., explain how precision therapeutics can improve treatment for patients with major depressive disorder. The optimal antidepressant medication and dose vary among individuals. Pharmacogenomic testing and therapeutic drug monitoring can guide clinicians to the most-effective treatment for each patient.

Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.